David C. Madoff, Interventional Oncologist, Vice Chair for Clinical Research, Section Chief, Interventional Radiology at Yale University School of Medicine, shared a post on LinkedIn:
“What a great day at Yale’s Advancing Care in Liver Cancer: Surveillance, Team-Based Care, and Emerging Therapies — A Patient and Community Symposium!
It was wonderful to bring together patients, families, members of the community, and experts from across our multidisciplinary liver cancer team for a day of informative presentations and engaging discussions.
I had the opportunity to speak about integrating liver-directed therapies into multidisciplinary liver cancer care. Throughout the program, there were many thoughtful questions from attendees, leading to valuable discussions about the different aspects of liver cancer care. A particular highlight was hearing from two patients who shared their personal experiences with liver cancer.
The multidisciplinary approach is particularly important in liver cancer, where patients may benefit from a number of different treatment options throughout the course of their care.
The symposium was also recorded, and we hope to share the presentations with those who were unable to attend.
Many thanks to the organizers, speakers, and especially the patients and families who joined us and contributed to such a successful program.”
You can also read: Phase 3b SIERRA: Durvalumab Plus Tremelimumab in Poor-Prognosis Unresectable HCC
